{"id":22103,"date":"2023-04-27T07:00:00","date_gmt":"2023-04-27T07:00:00","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/press-releases\/ipsen-enregistre-une-solide-croissance-de-ses-ventes-au-premier-trimestre-et-confirme-ses-objectifs-financiers-pour-lexercice-2023\/"},"modified":"2023-05-26T11:01:47","modified_gmt":"2023-05-26T11:01:47","slug":"ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance","status":"publish","type":"press_release","link":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/","title":{"rendered":"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l&#8217;exercice 2023"},"content":{"rendered":"\n<p><strong>Paris (France), 27 avril 2023<\/strong><\/p>\n\n\n\n<p>Ipsen (Euronext: IPN; ADR: IPSEY), Groupe biopharmaceutique mondial focalis\u00e9 sur la M\u00e9dicine de Sp\u00e9cialit\u00e9, publie aujourd\u2019hui son chiffre d\u2019affaires pour le premier trimestre 2023.<\/p>\n\n\n\n<div class=\"table-scroll\">\n<table width=\"100%\">\n<tbody>\n<tr>\n<td rowspan=\"2\" width=\"40%\">&nbsp;<\/td>\n<td width=\"2%\">&nbsp;<\/td>\n<td width=\"14%\"><strong>T1 2023<\/strong><\/td>\n<td width=\"14%\"><strong>T1 2022<\/strong><\/td>\n<td colspan=\"2\" width=\"28%\"><strong>% variation<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"2%\">&nbsp;<\/td>\n<td width=\"14%\"><strong>(M\u20ac)<\/strong><\/td>\n<td width=\"14%\"><strong>(M\u20ac)<\/strong><\/td>\n<td width=\"14%\"><strong>R\u00e9alis\u00e9<\/strong><\/td>\n<td width=\"14%\"><strong>TCC<sup>1<\/sup><\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"40%\">Oncologie<\/td>\n<td width=\"2%\">&nbsp;<\/td>\n<td width=\"14%\">570,8<\/td>\n<td width=\"14%\">556,4<\/td>\n<td width=\"14%\">2,6%<\/td>\n<td width=\"14%\">1,1%<\/td>\n<\/tr>\n<tr>\n<td width=\"40%\">Neurosciences<\/td>\n<td width=\"2%\">&nbsp;<\/td>\n<td width=\"14%\">156,4<\/td>\n<td width=\"14%\">120,2<\/td>\n<td width=\"14%\">30,2%<\/td>\n<td width=\"14%\">24,4%<\/td>\n<\/tr>\n<tr>\n<td width=\"40%\">Maladies&nbsp;Rares<\/td>\n<td width=\"2%\">&nbsp;<\/td>\n<td width=\"14%\">14,7<\/td>\n<td width=\"14%\">11,3<\/td>\n<td width=\"14%\">29,8%<\/td>\n<td width=\"14%\">29,0%<\/td>\n<\/tr>\n<tr>\n<td width=\"40%\"><strong>Chiffre d\u2019affaires Groupe<sup>2<\/sup><\/strong><\/td>\n<td width=\"2%\">&nbsp;<\/td>\n<td width=\"14%\"><strong>741,9<\/strong><\/td>\n<td width=\"14%\"><strong>687,9<\/strong><\/td>\n<td width=\"14%\"><strong>7,8%<\/strong><\/td>\n<td width=\"14%\"><strong>5,7%<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<p><strong>Faits marquants<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Croissance des ventes de 5,7% \u00e0 taux de change constant<sup>1<\/sup>, ou de 7,8% en donn\u00e9es publi\u00e9es, tir\u00e9e par les performances des plateformes de croissance<sup>3<\/sup>, en hausse de 14,7%<sup>1<\/sup>, avec une augmentation de 25,2%<sup>1<\/sup>&nbsp;pour Dysport<sup>\u00ae<\/sup>&nbsp;(abobotulinumtoxinA) et de 31,0%<sup>1<\/sup>&nbsp;pour Cabometyx<sup>\u00ae<\/sup>&nbsp;(cabozantinib). Contribution des produits r\u00e9cemment acquis Tazverik<sup>\u00ae<\/sup>&nbsp;(tazemetostat) et Bylvay<sup>\u00ae<\/sup>&nbsp;(odevixibat) \u00e0 la performance des ventes.<\/li>\n\n\n\n<li>Finalisation de l\u2019accord de fusion d\u00e9finitif d\u2019acquisition d\u2019Albireo, renfor\u00e7ant la pr\u00e9sence du Groupe dans les Maladies Rares.<\/li>\n\n\n\n<li>Confirmation des dates par les autorit\u00e9s r\u00e9glementaires am\u00e9ricaines pour statuer sur l\u2019approbation de Bylvay dans le syndrome d\u2019Alagille et du palovarot\u00e8ne dans la fibrodysplasie ossifiante progressive (FOP).<\/li>\n\n\n\n<li>Confirmation des objectifs financiers annuels pour l\u2019exercice 2023, avec une croissance du chiffre d\u2019affaires Groupe sup\u00e9rieure \u00e0 4,0% \u00e0 taux de change constant<sup>1<\/sup>&nbsp;et une marge op\u00e9rationnelle des activit\u00e9s d\u2019environ 30% du chiffre d\u2019affaires Groupe.<\/li>\n<\/ul>\n\n\n\n<p><strong>David Loew, Directeur g\u00e9n\u00e9ral d\u2019Ipsen, a d\u00e9clar\u00e9&nbsp;:<\/strong><\/p>\n\n\n\n<p>\u00ab Ipsen continue de faire d\u2019excellents progr\u00e8s dans son plan de transformation. Nous affichons une solide croissance de nos ventes au premier trimestre, port\u00e9es par les excellentes performances du Dysport et Cabometyx. Compte tenu de la bonne dynamique des ventes, nous confirmons nos objectifs financiers pour l\u2019ensemble de l\u2019exercice 2023. Je me r\u00e9jouis \u00e9galement de voir s\u2019\u00e9toffer notre portefeuille de R&amp;D, notre portefeuille de produits commercialis\u00e9s et nos \u00e9quipes \u00e0 la suite de la r\u00e9cente acquisition d\u2019Albireo. Gr\u00e2ce \u00e0 notre pr\u00e9sence mondiale, Ipsen continuera de r\u00e9pondre aux besoins m\u00e9dicaux non satisfaits d\u2019un nombre croissant de patients. Alors que nous renfor\u00e7ons notre portefeuille de produits en R&amp;D et nous int\u00e9grons nos r\u00e9centes acquisitions, nous anticipons plusieurs \u00e9tapes importantes, telles que les r\u00e9sultats de Phase III pour elafibranor et des nouvelles avanc\u00e9es r\u00e9glementaires anticip\u00e9es pour Onivyde, palovarot\u00e8ne et Bylvay&nbsp;\u00bb<\/p>\n\n\n\n<p><strong>Objectifs financiers pour 2023<\/strong><\/p>\n\n\n\n<p>Ipsen a confirm\u00e9 ses objectifs financiers pour l\u2019exercice 2023<sup>4<\/sup>&nbsp;:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Croissance du chiffre d\u2019affaires Groupe sup\u00e9rieure \u00e0 4,0%, \u00e0 taux de change constants. Sur la base des taux de change moyens du premier trimestre 2023, Ipsen anticipe un impact d\u00e9favorable des devises de l\u2019ordre de 2% sur le chiffre d\u2019affaires Groupe.<\/li>\n\n\n\n<li>Marge op\u00e9rationnelle des activit\u00e9s d\u2019environ 30&nbsp;% du chiffre d\u2019affaires Groupe, hors impact potentiel&nbsp;d\u2019investissements&nbsp;additionnels dans le cadre de l\u2019innovation externe.<\/li>\n<\/ul>\n\n\n\n<p><strong>Business D\u00e9veloppement<\/strong><\/p>\n\n\n\n<p>En mars 2023, Ipsen a annonc\u00e9 avoir finalis\u00e9 l\u2019acquisition d\u2019Albireo&nbsp;Pharma,&nbsp;Inc., une entreprise innovante de premier plan dans le domaine des modulateurs d\u2019acides biliaires pour le traitement des maladies h\u00e9patiques rares. Ipsen a acquis toutes les actions \u00e9mises et en circulation d\u2019Albireo au prix de 42,00&nbsp;$ par action en num\u00e9raire, auquel s\u2019ajoute un Certificat de Valeur Garantie (CVG) non transf\u00e9rable de 10,00&nbsp;$ par action.<\/p>\n\n\n\n<p><strong>D\u00e9veloppement du portefeuille de produits en R&amp;D<\/strong><\/p>\n\n\n\n<p>En f\u00e9vrier 2023, Ipsen a annonc\u00e9 que les autorit\u00e9s am\u00e9ricaines (Food and Drug Administration) ont accept\u00e9 la nouvelle demande d\u2019approbation de Bylvay dans le cadre d\u2019une deuxi\u00e8me indication chez les patients atteints du syndrome d\u2019Alagille. La FDA a \u00e9galement communiqu\u00e9 une date butoir en vertu de la loi am\u00e9ricaine Prescription Drug User Fee Act (PDUFA), le 15 juin 2023.<\/p>\n\n\n\n<p>En mars 2023, Ipsen a annonc\u00e9 que les autorit\u00e9s r\u00e9glementaires am\u00e9ricaines (FDA) ont communiqu\u00e9 une nouvelle date au titre du PDUFA, le 16 ao\u00fbt 2023, pour r\u00e9pondre \u00e0 la nouvelle demande d\u2019approbation du palovarot\u00e8ne comme traitement potentiel de la fibrodysplasie ossifiante progressive (FOP). Le Groupe a \u00e9galement r\u00e9cemment demand\u00e9 au CHMP<sup>5<\/sup><a href=\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-publie-aujourdhui-son-chiffre-daffaires-pour-le-premier-trimestre-2023\/#_ftn5\" name=\"_ftnref5\"><\/a>&nbsp;de r\u00e9examiner sa position communiqu\u00e9e en janvier 2023 sur le palovarot\u00e8ne.<\/p>\n\n\n\n<p><strong>Conf\u00e9rence t\u00e9l\u00e9phonique (en anglais)<\/strong><\/p>\n\n\n\n<p>Une conf\u00e9rence t\u00e9l\u00e9phonique et un webcast destin\u00e9s aux investisseurs et analystes se tiendront aujourd\u2019hui \u00e0 14h, heure de Paris. Les participants peuvent acc\u00e9der \u00e0 la conf\u00e9rence et aux informations correspondantes via ce&nbsp;<a href=\"https:\/\/register.vevent.com\/register\/BI5e3446b2e9a44307b3f6bba31913a71d\">lien<\/a>. Pour en savoir plus sur le webcast, toutes les informations n\u00e9cessaires sont disponibles&nbsp;<a href=\"http:\/\/ipsen.to\/q1_2023_webcast\">ici<\/a>. Un enregistrement sera disponible sur le site Internet&nbsp;<a href=\"https:\/\/d3glparxwv1yl3.cloudfront.net\/\">ipsen.com<\/a>.<\/p>\n\n\n\n<p><strong>Calendrier<\/strong><\/p>\n\n\n\n<p>Ipsen pr\u00e9voit de publier ses r\u00e9sultats du premier semestre et du deuxi\u00e8me trimestre le 27 juillet 2023.<\/p>\n\n\n\n<p><strong>Notes<\/strong><\/p>\n\n\n\n<p>Tous les chiffres financiers sont exprim\u00e9s en millions d\u2019euros. Sauf indication contraire, les performances publi\u00e9es dans le pr\u00e9sent communiqu\u00e9 couvrent la p\u00e9riode de trois mois courant jusqu\u2019au 31 mars 2023 (le premier trimestre ou T1 2023), comparativement \u00e0 la p\u00e9riode de trois mois jusqu\u2019au 31 mars 2022 (T1 2022).<\/p>\n\n\n\n<p><strong>Ipsen<\/strong><\/p>\n\n\n\n<p>Ipsen est une soci\u00e9t\u00e9 biopharmaceutique mondiale de taille moyenne focalis\u00e9e sur la mise au point de m\u00e9dicaments innovants en Oncologie, dans les Maladies Rares et en Neurosciences. Avec un chiffre d\u2019affaires Groupe de 3,0 milliards d\u2019euros pour l\u2019exercice 2022, Ipsen vend des m\u00e9dicaments dans plus de 100 pays. Outre sa strat\u00e9gie d\u2019innovation externe, les efforts d\u2019Ipsen en mati\u00e8re de R&amp;D sont focalis\u00e9s sur ses plateformes technologiques diff\u00e9renci\u00e9es et innovantes situ\u00e9es au c\u0153ur de clusters mondiaux de la recherche biotechnologique ou en sciences de la vie : Paris-Saclay, France ; Oxford, Royaume-Uni ; Cambridge, \u00c9tats-Unis&nbsp;; Shanghai, Chine. Ipsen emploie environ 5 400 collaborateurs dans le monde. Ipsen est cot\u00e9 \u00e0 Paris (Euronext&nbsp;: IPN) et aux \u00c9tats-Unis \u00e0 travers un programme d\u2019American Depositary Receipt (ADR : IPSEY) sponsoris\u00e9 de niveau I. Le site Internet d\u2019Ipsen est ipsen.com.<\/p>\n\n\n\n<div class=\"table-scroll\">\n<table width=\"655\">\n<tbody>\n<tr>\n<td width=\"406\"><strong>Contacts<\/strong><\/td>\n<td width=\"248\">&nbsp;<\/td>\n<\/tr>\n<tr>\n<td width=\"406\"><strong><u>Investisseurs<\/u><\/strong><\/td>\n<td width=\"248\">&nbsp;<\/td>\n<\/tr>\n<tr>\n<td width=\"406\"><strong>Craig Marks<\/strong>\n<p>&nbsp;<\/p>\n<p>Vice-Pr\u00e9sident, Relations Investisseurs<\/p>\n<p>+44 (0)7584 349 193<\/p>\n<\/td>\n<td width=\"248\">&nbsp;<\/td>\n<\/tr>\n<tr>\n<td width=\"406\">\n<p><strong><u>M\u00e9dias<\/u><\/strong><\/p>\n<\/td>\n<td width=\"248\">&nbsp;<\/td>\n<\/tr>\n<tr>\n<td width=\"406\"><strong>Amy Wolf<\/strong>\n<p>&nbsp;<\/p>\n<p>Vice-Pr\u00e9sidente, Strat\u00e9gie de la marque Corporate<\/p>\n<p>et Communication<\/p>\n<p>+41 79 576 07 23<\/p>\n<p><strong>&nbsp;<\/strong><\/p>\n<\/td>\n<td width=\"248\"><strong>Ioana&nbsp;Piscociu<\/strong>\n<p>&nbsp;<\/p>\n<p>Responsable Senior,<\/p>\n<p>Global Media Relations<\/p>\n<p>+33 6 69 09 12 96<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div class=\"article-sources\">\n<ol>\n<li>Variation \u00e0 taux de change constant, hors effets de change, \u00e9tabli en recalculant les performances de la p\u00e9riode consid\u00e9r\u00e9e sur la base des taux de change utilis\u00e9s pour la p\u00e9riode pr\u00e9c\u00e9dente.<\/li>\n<li>Le chiffre d\u2019affaires mentionn\u00e9 dans le pr\u00e9sent communiqu\u00e9 est un chiffre d\u2019affaires consolid\u00e9 IFRS non audit\u00e9.<\/li>\n<li>Dysport, D\u00e9capeptyl<sup>\u00ae<\/sup>&nbsp;(triptor\u00e9line), Cabometyx et Onivyde<sup>\u00ae<\/sup>&nbsp;(irinot\u00e9can).<\/li>\n<li>Les performances de l\u2019activit\u00e9 Sant\u00e9 Familiale, c\u00e9d\u00e9e en juillet 2022, ont \u00e9t\u00e9 exclues de l\u2019ensemble des commentaires et comparaisons avec les performances ant\u00e9rieures.<\/li>\n<li>Le comit\u00e9 des m\u00e9dicaments \u00e0 usage humain (CHMP) de l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA), responsable des m\u00e9dicaments \u00e0 usage humain.<\/li>\n<\/ol>\n<\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"template":"","categories":[3556,3557,6364],"tags":[],"class_list":["post-22103","press_release","type-press_release","status-publish","has-post-thumbnail","hentry","category-corporate-pressrelease-fr","category-financial-pressrelease-fr","category-regulated-info-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l&#039;exercice 2023 - Global<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l&#039;exercice 2023 - Global\" \/>\n<meta property=\"og:url\" content=\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-26T11:01:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1082\" \/>\n\t<meta property=\"og:image:height\" content=\"620\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/\",\"name\":\"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2023 - Global\",\"isPartOf\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg\",\"datePublished\":\"2023-04-27T07:00:00+00:00\",\"dateModified\":\"2023-05-26T11:01:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg\",\"width\":1082,\"height\":620},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/accueil\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l&#8217;exercice 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#website\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2023 - Global","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2023 - Global","og_url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/","og_site_name":"Global","article_modified_time":"2023-05-26T11:01:47+00:00","og_image":[{"width":1082,"height":620,"url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/","name":"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2023 - Global","isPartOf":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/#primaryimage"},"image":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg","datePublished":"2023-04-27T07:00:00+00:00","dateModified":"2023-05-26T11:01:47+00:00","breadcrumb":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/#primaryimage","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28112625\/PR-final-fr-1.jpg","width":1082,"height":620},{"@type":"BreadcrumbList","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/press-releases\/ipsen-delivers-robust-sales-growth-in-the-first-quarter-of-2023-and-confirms-its-full-year-guidance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/accueil\/"},{"@type":"ListItem","position":2,"name":"Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l&#8217;exercice 2023"}]},{"@type":"WebSite","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#website","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#organization","name":"IPSEN","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"_links":{"self":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/press_release\/22103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/users\/2"}],"version-history":[{"count":0,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/press_release\/22103\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/media\/27874"}],"wp:attachment":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/media?parent=22103"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/categories?post=22103"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/fr\/wp-json\/wp\/v2\/tags?post=22103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}